Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-03

Clinical Trial Update: Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating synthetic thyrotropin releasing hormone (TRH) for cancer-related fatigue was terminated; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Thyrotropin releasing hormone (TRH) (thyrotropin releasing hormone)

Snippet

Sponsor: UConn Health | Conditions: Cancer-related Fatigue | Phase 2 | Status: TERMINATED | Results posted: 2011-05-03